Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dianthus Therapeutics ( (DNTH) ) has shared an announcement.
On October 16, 2025, Dianthus Therapeutics entered into a License and Collaboration Agreement with Nanjing Leads Biolabs, granting Dianthus an exclusive license outside Greater China to develop and commercialize DNTH212, a bifunctional fusion protein targeting immune system pathways. This agreement involves significant financial commitments, including up to $38 million in upfront and milestone payments, and potential royalties for Leads. The collaboration aims to enhance Dianthus’ position in the autoimmune disease therapeutics market, with DNTH212 showing potential for superior clinical efficacy compared to existing treatments.
The most recent analyst rating on (DNTH) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Dianthus Therapeutics stock, see the DNTH Stock Forecast page.
Spark’s Take on DNTH Stock
According to Spark, TipRanks’ AI Analyst, DNTH is a Neutral.
Dianthus Therapeutics’ overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and significant losses. While technical analysis shows bullish momentum, the stock is overbought, indicating potential volatility. The negative P/E ratio and lack of dividend yield further weigh down the valuation score.
To see Spark’s full report on DNTH stock, click here.
More about Dianthus Therapeutics
Dianthus Therapeutics is a company in the biotechnology industry focused on developing next-generation therapeutics. The company specializes in investigational agents targeting immune system pathways, with a market focus on autoimmune diseases.
Average Trading Volume: 657,856
Technical Sentiment Signal: Buy
Current Market Cap: $1.44B
Learn more about DNTH stock on TipRanks’ Stock Analysis page.